Trial Profile
CD19 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed non - Hodgkin's lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jun 2019
Price :
$35
*
At a glance
- Drugs Anti cd19 CAR T cell therapy Innovative Cellular Therapeutics (Primary)
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 16 Aug 2018 New trial record